1.
Hosp Pharm
; 49(6): 539-43, 2014 Jun.
Artículo
en Inglés
| MEDLINE
| ID: mdl-24958971
RESUMEN
Bupivacaine liposomal injection was recently approved by the US Food and Drug Administration (FDA) as a local anesthetic for use in management of postsurgical pain in adults. When compared to placebo, bupivacaine liposomal decreases postoperative pain and opioid use. This review examines the efficacy of bupivacaine liposomal when compared to conventional bupivacaine ± epinephrine using published and unpublished data provided to the FDA by the manufacturer.